Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pegcetacoplan

Pegcetacoplan Pegcetacoplan is a complement inhibitor. Class: 92:32 • Complement Inhibitors (AHFS primary) Brands: Empaveli® Boxed Warning WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA See full prescribing information for complete boxed warning. Meningococcal infections may occur in patients treated with pegcetacoplan and may become rapidly life-threatening or fatal if not recognized and treated early. Use of pegcetacoplan may predispose individuals to serious infections, especially those caused by encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria. Vaccinate patients against encapsulated bacteria as recommended at least 2 weeks prior to administering the first dose of pegcetacoplan unless the risks of delaying pegcetacoplan therapy outweigh the risks of developing a serious infection. See the manufacturer’s labeling for additional guidance on managing the risk of serious infections. Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected. Pegcetacoplan is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the pegcetacoplan REMS, prescribers must enroll in the program. REMS FDA approved a REMS for pegcetacoplan to ensure that the benefits outweigh the risk. The REMS may apply to one or more preparations of pegcetacoplan. See the FDA REMS page (http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm). Uses Pegcetacoplan has the following uses: Pegcetacoplan is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Dosage and Administration General Pegcetacoplan is available in the following dosage form(s) and strength(s): Injection: 1080 mg/20 mL (54 mg/mL) in a single-dose vial. Dosage It is essential that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary: Adults Dosage and Administration Recommended dosage is 1080 mg by subcutaneous infusion twice weekly via a commercially available pump. See the manufacturer’s labeling for instructions on preparation and administration. Cautions Contraindications Pegcetacoplan is contraindicated in: Patients with hypersensitivity to pegcetacoplan or any of the ingredients in the formulation. Patients who are not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying pegcetacoplan treatment outweigh the risks of developing a serious bacterial infection with an encapsulated organism. Patients with unresolved serious infection caused by encapsulated bacteria. Warnings/Precautions Serious Infections Caused by Encapsulated Bacteria The use of pegcetacoplan may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with pegcetacoplan. For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of pegcetacoplan. If immediate therapy with pegcetacoplan is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis. Use caution when administering pegcetacoplan to patients with serious infections caused by encapsulated bacteria. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of pegcetacoplan in patients who are undergoing treatment for serious infections. Pegcetaclopan REMS Because of the risk of serious infections, pegcetacoplan is available only through a restricted program under a REMS. Under the pegcetacoplan REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of serious infection, provide patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment in the pegcetacoplan REMS and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com. Infusion-related Reactions Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with pegcetacoplan. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. Use caution when administering pegcetacoplan to patients with infusion-related reactions. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue pegcetacoplan infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved. Monitoring PNH Manifestations after Discontinuation of Pegcetacoplan After discontinuing treatment with pegcetacoplan, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues pegcetacoplan for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of pegcetacoplan, consider restarting treatment with pegcetacoplan. Interference with Laboratory Tests There may be interference between silica reagents in coagulation panels and pegcetacoplan that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels. Specific Populations Pregnancy Risk Summary: There are insufficient data on pegcetacoplan use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated PNH in pregnancy. Treatment of pregnant cynomolgus monkeys with pegcetacoplan at a subcutaneous dose of 28 mg/kg/day (2.9 times human exposure based on AUC) from the gestation period through parturition resulted in a statistically significant increase in abortions or stillbirths compared to controls. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Disease-associated Maternal and/or Fetal/Neonatal Risk: PNH in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery. Animal Data: Animal reproduction studies with pegcetacoplan were conducted in cynomolgus monkeys. Pegcetacoplan treatment of pregnant cynomolgus monkeys at a subcutaneous dose of 28 mg/kg/day (2.9 times human exposure based on AUC) from the gestation period through parturition resulted in a statistically significant increase in abortions and stillbirths compared to controls. No increase in abortions or stillbirths occurred at a dose of 7 mg/kg/day (1.3 times human exposure based on AUC). No maternal toxicity or teratogenic effects were observed in offspring delivered at term. No developmental effects were observed in infants up to 6 months postpartum. Systemic exposure to pegcetacoplan of less than 1% of maternal levels was detected in fetuses from monkeys treated with 28 mg/kg/day from the period of organogenesis through the second trimester. Lactation Risk Summary: It is not known whether pegcetacoplan is secreted in human milk or whether there is potential for absorption and harm to the infant. There are no data on the effects of pegcetacoplan on milk production. Pegcetacoplan is present in milk of lactating monkeys. Since many medicinal products are secreted into human milk, and because of the potential for serious adverse reaction in a breastfeeding child, breastfeeding should be discontinued during treatment and for 40 days after the last dose. Animal Data: Pegcetacoplan was detectable in milk of lactating monkeys at less than 1% concentration of serum levels but was not detectable in the serum of nursing infants. Females and Males of Reproductive Potential Pegcetacoplan may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with pegcetacoplan. Advise female patients of reproductive potential to use effective contraception during treatment with pegcetacoplan and for 40 days after the last dose. Pediatric Use Safety and effectiveness have not been established. Geriatric Use Clinical studies of pegcetacoplan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between geriatric and younger patients. Common Adverse Effects Most common adverse reactions in patients with PNH (incidence ≥10%) were injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue. Interactions Specific Drugs It is essential that the manufacturer’s labeling be consulted for more detailed information on interactions with this drug, including possible dosage adjustments. Interaction highlights: Please see product labeling for drug interaction information. Actions Mechanism of Action Pegcetacoplan binds to complement protein C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation. In PNH, extravascular hemolysis (EVH) is facilitated by C3b opsonization while intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC). Pegcetacoplan acts proximally in the complement cascade controlling both C3b-mediated EVH and terminal complement-mediated IVH. Advice to Patients Advise patients of the risk of serious infection. Inform patients that they are required to receive vaccinations against encapsulated bacteria at least 2 weeks prior to receiving the first dose of pegcetacoplan if they have not been previously vaccinated. They are required to be revaccinated according to current medical guidelines for encapsulated bacteria while on pegcetacoplan therapy. Inform patients that vaccination may not prevent serious infection and strongly advise patients to seek immediate medical attention if these signs or symptoms occur. These signs and symptoms include the following: fever with or without shivers or the chills, fever and a rash, shortness of breath, extreme pain or discomfort, headache with nausea or vomiting, high heart rate, headache and a fever, headache with a stiff neck or stiff back, confusion, muscle aches with flulike symptoms, clammy skin, eyes sensitive to light. Inform patients that they will be given a Patient Safety Card for pegcetacoplan that they should carry with them at all times. This card describes symptoms which, if experienced, should prompt the patient to seek immediate medical evaluation. Advise patients of the risk of anaphylaxis and infusion-related reactions. Inform patients that anaphylaxis is life-threatening and strongly advise patients to seek immediate medical attention if these signs or symptoms occur. These signs and symptoms include the following: difficulty breathing, including shortness of breath and wheezing; swollen tongue or throat; feeling faint; rapid heart rate; skin reactions, including hives and itching; nausea or vomiting; confusion and anxiety; dizziness or fainting. Inform patients with PNH that they may develop hemolysis due to PNH when pegcetacoplan is discontinued and that they will be monitored by their healthcare professional for at least 8 weeks following discontinuation of the drug. Inform patients who discontinue pegcetacoplan to keep the Patient Safety Card with them for 2 months after the last dose because the increased risk of serious infection persists for several weeks following discontinuation of the drug. Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Open in new tab Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Open in new tab © Copyright, June 28, 2021, American Society of Health-System Pharmacists, Inc. Published by Oxford University Press on behalf of the American Society of Health-System Pharmacists 2021. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Health-System Pharmacy Oxford University Press

Pegcetacoplan

American Journal of Health-System Pharmacy , Volume Advance Article – Jul 16, 2021

Loading next page...
 
/lp/oxford-university-press/pegcetacoplan-DxnB4AcPjo

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2021 American Society of Health-System Pharmacists
ISSN
1079-2082
eISSN
1535-2900
DOI
10.1093/ajhp/zxab267
Publisher site
See Article on Publisher Site

Abstract

Pegcetacoplan is a complement inhibitor. Class: 92:32 • Complement Inhibitors (AHFS primary) Brands: Empaveli® Boxed Warning WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA See full prescribing information for complete boxed warning. Meningococcal infections may occur in patients treated with pegcetacoplan and may become rapidly life-threatening or fatal if not recognized and treated early. Use of pegcetacoplan may predispose individuals to serious infections, especially those caused by encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria. Vaccinate patients against encapsulated bacteria as recommended at least 2 weeks prior to administering the first dose of pegcetacoplan unless the risks of delaying pegcetacoplan therapy outweigh the risks of developing a serious infection. See the manufacturer’s labeling for additional guidance on managing the risk of serious infections. Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected. Pegcetacoplan is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the pegcetacoplan REMS, prescribers must enroll in the program. REMS FDA approved a REMS for pegcetacoplan to ensure that the benefits outweigh the risk. The REMS may apply to one or more preparations of pegcetacoplan. See the FDA REMS page (http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm). Uses Pegcetacoplan has the following uses: Pegcetacoplan is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Dosage and Administration General Pegcetacoplan is available in the following dosage form(s) and strength(s): Injection: 1080 mg/20 mL (54 mg/mL) in a single-dose vial. Dosage It is essential that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary: Adults Dosage and Administration Recommended dosage is 1080 mg by subcutaneous infusion twice weekly via a commercially available pump. See the manufacturer’s labeling for instructions on preparation and administration. Cautions Contraindications Pegcetacoplan is contraindicated in: Patients with hypersensitivity to pegcetacoplan or any of the ingredients in the formulation. Patients who are not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying pegcetacoplan treatment outweigh the risks of developing a serious bacterial infection with an encapsulated organism. Patients with unresolved serious infection caused by encapsulated bacteria. Warnings/Precautions Serious Infections Caused by Encapsulated Bacteria The use of pegcetacoplan may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with pegcetacoplan. For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of pegcetacoplan. If immediate therapy with pegcetacoplan is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis. Use caution when administering pegcetacoplan to patients with serious infections caused by encapsulated bacteria. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of pegcetacoplan in patients who are undergoing treatment for serious infections. Pegcetaclopan REMS Because of the risk of serious infections, pegcetacoplan is available only through a restricted program under a REMS. Under the pegcetacoplan REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risk of serious infection, provide patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment in the pegcetacoplan REMS and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com. Infusion-related Reactions Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with pegcetacoplan. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. Use caution when administering pegcetacoplan to patients with infusion-related reactions. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue pegcetacoplan infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved. Monitoring PNH Manifestations after Discontinuation of Pegcetacoplan After discontinuing treatment with pegcetacoplan, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues pegcetacoplan for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of pegcetacoplan, consider restarting treatment with pegcetacoplan. Interference with Laboratory Tests There may be interference between silica reagents in coagulation panels and pegcetacoplan that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels. Specific Populations Pregnancy Risk Summary: There are insufficient data on pegcetacoplan use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated PNH in pregnancy. Treatment of pregnant cynomolgus monkeys with pegcetacoplan at a subcutaneous dose of 28 mg/kg/day (2.9 times human exposure based on AUC) from the gestation period through parturition resulted in a statistically significant increase in abortions or stillbirths compared to controls. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Disease-associated Maternal and/or Fetal/Neonatal Risk: PNH in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery. Animal Data: Animal reproduction studies with pegcetacoplan were conducted in cynomolgus monkeys. Pegcetacoplan treatment of pregnant cynomolgus monkeys at a subcutaneous dose of 28 mg/kg/day (2.9 times human exposure based on AUC) from the gestation period through parturition resulted in a statistically significant increase in abortions and stillbirths compared to controls. No increase in abortions or stillbirths occurred at a dose of 7 mg/kg/day (1.3 times human exposure based on AUC). No maternal toxicity or teratogenic effects were observed in offspring delivered at term. No developmental effects were observed in infants up to 6 months postpartum. Systemic exposure to pegcetacoplan of less than 1% of maternal levels was detected in fetuses from monkeys treated with 28 mg/kg/day from the period of organogenesis through the second trimester. Lactation Risk Summary: It is not known whether pegcetacoplan is secreted in human milk or whether there is potential for absorption and harm to the infant. There are no data on the effects of pegcetacoplan on milk production. Pegcetacoplan is present in milk of lactating monkeys. Since many medicinal products are secreted into human milk, and because of the potential for serious adverse reaction in a breastfeeding child, breastfeeding should be discontinued during treatment and for 40 days after the last dose. Animal Data: Pegcetacoplan was detectable in milk of lactating monkeys at less than 1% concentration of serum levels but was not detectable in the serum of nursing infants. Females and Males of Reproductive Potential Pegcetacoplan may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with pegcetacoplan. Advise female patients of reproductive potential to use effective contraception during treatment with pegcetacoplan and for 40 days after the last dose. Pediatric Use Safety and effectiveness have not been established. Geriatric Use Clinical studies of pegcetacoplan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between geriatric and younger patients. Common Adverse Effects Most common adverse reactions in patients with PNH (incidence ≥10%) were injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue. Interactions Specific Drugs It is essential that the manufacturer’s labeling be consulted for more detailed information on interactions with this drug, including possible dosage adjustments. Interaction highlights: Please see product labeling for drug interaction information. Actions Mechanism of Action Pegcetacoplan binds to complement protein C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation. In PNH, extravascular hemolysis (EVH) is facilitated by C3b opsonization while intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC). Pegcetacoplan acts proximally in the complement cascade controlling both C3b-mediated EVH and terminal complement-mediated IVH. Advice to Patients Advise patients of the risk of serious infection. Inform patients that they are required to receive vaccinations against encapsulated bacteria at least 2 weeks prior to receiving the first dose of pegcetacoplan if they have not been previously vaccinated. They are required to be revaccinated according to current medical guidelines for encapsulated bacteria while on pegcetacoplan therapy. Inform patients that vaccination may not prevent serious infection and strongly advise patients to seek immediate medical attention if these signs or symptoms occur. These signs and symptoms include the following: fever with or without shivers or the chills, fever and a rash, shortness of breath, extreme pain or discomfort, headache with nausea or vomiting, high heart rate, headache and a fever, headache with a stiff neck or stiff back, confusion, muscle aches with flulike symptoms, clammy skin, eyes sensitive to light. Inform patients that they will be given a Patient Safety Card for pegcetacoplan that they should carry with them at all times. This card describes symptoms which, if experienced, should prompt the patient to seek immediate medical evaluation. Advise patients of the risk of anaphylaxis and infusion-related reactions. Inform patients that anaphylaxis is life-threatening and strongly advise patients to seek immediate medical attention if these signs or symptoms occur. These signs and symptoms include the following: difficulty breathing, including shortness of breath and wheezing; swollen tongue or throat; feeling faint; rapid heart rate; skin reactions, including hives and itching; nausea or vomiting; confusion and anxiety; dizziness or fainting. Inform patients with PNH that they may develop hemolysis due to PNH when pegcetacoplan is discontinued and that they will be monitored by their healthcare professional for at least 8 weeks following discontinuation of the drug. Inform patients who discontinue pegcetacoplan to keep the Patient Safety Card with them for 2 months after the last dose because the increased risk of serious infection persists for several weeks following discontinuation of the drug. Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Open in new tab Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Pegcetacoplan Parenteral Injection, for subcutaneous infusion via controlled-infusion device only 54 mg/mL Empaveli®, Apellis Pharmaceuticals Open in new tab © Copyright, June 28, 2021, American Society of Health-System Pharmacists, Inc. Published by Oxford University Press on behalf of the American Society of Health-System Pharmacists 2021. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Journal

American Journal of Health-System PharmacyOxford University Press

Published: Jul 16, 2021

There are no references for this article.